MAY 24, 2019 10:14 PM PDT

First Anticoagulant Approved for Pediatric Patients to Treat Potentially Life-Threatening Blood Clots

WRITTEN BY: Nouran Amin

The approval of the drug Fragmin, an anti-coagulant subcutaneous use, will seek to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients—which can include deep vein thrombosis and pulmonary embolism that may lead to death.

VTE can develop as a secondary complication from a broad spectrum of underlying clinical conditions such as a venous catheter, cancer, infection, congenital heart disease, and trauma or surgery and is associated with an increased risk of in-hospital mortality.

Although Fragmin was approved in 1994 for adult patients, it will be the first drug for the pediatric treatment for VTE.

Learn more about VTE:

“Most children who have VTE are fighting a serious underlying primary illness such as cancer or congenital heart disease. Not only are they fighting a serious illness, having a condition like VTE can then lead to significant complications and even death,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

Some issues with Fragmin may include bleeding and hemorrhage amongst other possible complications.

“Prior to this approval, there had been no FDA-approved therapies to treat VTE in pediatric patients. Given the unmet need, we granted the Fragmin application priority review and today we are approving it as the first anticoagulant (blood thinner) indicated for pediatric patients. We remain committed to advancing treatments for children with unmet medical needs.”

Source: Science Daily

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
AI Exponentially Accelerates Drug Development
Research and development for new drugs is both an expensive and lengthy process, often lasting years, if not decades. With the development of artificial in...
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
Injectable Drug reverses symptoms of liver disease in people with HIV
In a study conducted by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute, scientists report that an inje...
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
How Fluorescent Probes Can Enhance Drug Delivery
Researchers at Cornell University are working on improving the trial-and-error process that is implicated in finding effective molecules for drug delivery....
DEC 14, 2019
Neuroscience
DEC 14, 2019
Gene Mutation Identified that Protects Agaist Dementia
For over two decades, researchers have been studying an extended family of over 1,200 people from Columbia known for having a rare genetic mutation that le...
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
Psychedelic DMT Creates Vivid Waking Dream State in Brain
In a new study, scientists at Imperial College London investigated how powerful psychedelic dimethyltryptamine (DMT) alters the brain’s electrical ac...
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
Experimental Cholesterol-Lowering Drug
A recent study shows that patients who take a maximum dose of statin drugs in addition to a twice-yearly injection of the experimental cholesterol-lowering...
Loading Comments...